Regeneron Pharmaceuticals Inc (REGN)
A research Signal Score of unusual activity and the signals behind it. Not advice, not a prediction, not yet backtested.
Our last 30 days of resolved calls came true 29% of the time.See the track record →
Figures reflect the most recent reported period. Margins, ROE and growth are percentages; Debt/Equity and Current ratio are ratios.
A generic 2:1 reward-to-risk example (about a 10% stop and 20% target). Illustrative and educational, not advice. Set your own levels for your risk tolerance.
- 12-month trend+35% over the past year+3
- 52-week positionAbove the midpoint of its 52-week range+9
- QualityStrong net margin (28%)+4
- VolumeNo intraday volume on the free data tier — this factor is disabled, not faked.+0
Score uses live volume/momentum/breakout signals today; insider buying, short interest, options flow and social velocity layer in as those sources come online. How it works →
🤖 Dominant catalyst: none — the headlines are mostly comparative or retrospective, with no single company-specific event driving the stock. Continuation likelihood: roughly 40–50%, reflecting low momentum and no fresh fundamental trigger to sustain a directional move. Informational only — not financial advice.
- Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?Yahoo · 2026-09-04
- Black Diamond (BDTX) Up 9.4% Since Last Earnings Report: Can It Continue?Yahoo · 2026-09-04
- Trailing rivals, AbbVie scores win with dual-acting myeloma drugYahoo · 2026-09-04
- Why Is Veeva Systems (VEEV) Winning Big In AI For Biopharma?Yahoo · 2026-09-04
- Here’s How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 YearsBenzinga · 2026-09-02
Any AI summary is an interpretation of public news, not advice or a price target.